- Home
- AORT vs VRDN Comparison
AORT vs VRDN Comparison
Compare AORT & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AORT
- VRDN
- Stock Information
- Founded
- AORT 1984
- VRDN 2006
- Country
- AORT United States
- VRDN United States
- Employees
- AORT N/A
- VRDN N/A
- Industry
- AORT Medical/Dental Instruments
- VRDN Medical Specialities
- Sector
- AORT Health Care
- VRDN Health Care
- Exchange
- AORT Nasdaq
- VRDN Nasdaq
- Market Cap
- AORT 1.9B
- VRDN 1.6B
- IPO Year
- AORT 1993
- VRDN N/A
- Fundamental
- Price
- AORT $40.55
- VRDN $20.89
- Analyst Decision
- AORT Strong Buy
- VRDN Strong Buy
- Analyst Count
- AORT 6
- VRDN 11
- Target Price
- AORT $43.13
- VRDN $38.80
- AVG Volume (30 Days)
- AORT 422.4K
- VRDN 626.5K
- Earning Date
- AORT 11-06-2025
- VRDN 11-11-2025
- Dividend Yield
- AORT N/A
- VRDN N/A
- EPS Growth
- AORT N/A
- VRDN N/A
- EPS
- AORT N/A
- VRDN N/A
- Revenue
- AORT $405,037,000.00
- VRDN $305,000.00
- Revenue This Year
- AORT $14.99
- VRDN N/A
- Revenue Next Year
- AORT $10.80
- VRDN $34,076.08
- P/E Ratio
- AORT N/A
- VRDN N/A
- Revenue Growth
- AORT 7.44
- VRDN 5.90
- 52 Week Low
- AORT $21.97
- VRDN $9.90
- 52 Week High
- AORT $45.07
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- AORT 47.87
- VRDN 60.56
- Support Level
- AORT $38.95
- VRDN $20.69
- Resistance Level
- AORT $41.59
- VRDN $21.99
- Average True Range (ATR)
- AORT 1.04
- VRDN 0.91
- MACD
- AORT -0.27
- VRDN 0.07
- Stochastic Oscillator
- AORT 42.50
- VRDN 69.12
About AORT Artivion Inc.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).